HQS status for foreign pharma top executives following the 2024-2026 salary and Income tax reforms
In just two years, the minimum salary threshold for Highly Qualified Specialist (HQS) status has risen by 50%, while Personal Income Tax (PIT) for foreign executives changed from a simple flat rate into a five-tier progressive scale. At the same time, the state opened a path to permanent (indefinite) residence permits for foreign directors for the first time, removing the burden of annual migration renewals.
For a pharmaceutical company hiring a foreign Quality Director, Medical Director, or Regional Division Head, this creates two tasks at once: recalculate compensation budgets against the new thresholds, and adjust HR processes so the company does not lose the right to hire HQS staff for two years over a single overdue filing with the Ministry of Internal Affairs (MVD).
A case from pharma HR practice illustrates the shift. A Quality Director earning 2 million rubles a month used to pay a flat 13% PIT and renew their residence permit every three years alongside their work permit. Today, on the same salary, the employer withholds tax on a progressive scale. In exchange, after two years of employment the specialist becomes eligible for an indefinite residence permit and is no longer tied to a work permit at all.
How Companies Hired Foreign Executives Before 2024
The Highly Qualified Specialist (HQS) framework has existed in Russian law since 2010, under Article 13.2 of Federal Law No. 115-FZ of 25 July 2002, «On the Legal Status of Foreign Citizens in the Russian Federation» (hereinafter, FL-115). The employer assesses on its own whether a candidate holds unique experience and achievements in their field; the law does not require independent certification.
HQS status waives several procedures required for standard foreign workers: the company does not need a permit to recruit and employ foreign labor, is exempt from invitation quotas, and bypasses regional limits for most business activities. The work permit is issued for up to three years and allows multiple entries.
Before March 2024, the general salary threshold was 167,000 rubles a month, checked monthly. The residence permit for an HQS was strictly temporary, matching the duration of the work permit itself. Every time the work permit was renewed, the company had to reapply for a residence permit for the specialist and every family member. The main tax advantage of HQS status was a flat 13% PIT from day one of work in Russia, without the 183-day wait that ordinary foreign nationals face before reaching tax residency.
Even with these benefits, HQS status never fully exempted a company from migration tracking. Fingerprinting and a medical exam for infectious diseases remained mandatory for the specialist and dependents, and any change of employer effectively restarted the process. For pharmaceutical companies running multi-year projects (drug registration, market launch, manufacturing localization), this created a real risk of losing a project lead mid-cycle when a work permit expired.
Table 1. HQS status before and after the 2024-2026 reforms
| Parameter | Before March 2024 | After the 2024-2026 reforms |
|---|---|---|
| General salary threshold | 167,000 rubles a month | 750,000 rubles a quarter |
| Income monitoring frequency | Monthly | Quarterly |
| PIT rate | Flat 13% from day one | Progressive scale, 13-22%, from 2025 |
| Residence permit | Temporary, tied to the work permit | Indefinite, after 2 years of work |
| Deadline to collect the work permit card after MVD approval | No firmly fixed rule | 30 calendar days, or the permit is revoked |
| Currency transfers abroad for non-residents from non-friendly states | No specific cap tied to salary | Capped at the salary amount, in effect through 7 December 2026 |
Salary Thresholds and Tax Changes
Federal Law No. 316-FZ of 10 July 2023 rewrote the core parameters of HQS status. From 1 March 2024 the general threshold rose to 750,000 rubles a quarter, replacing the monthly calculation. Reduced thresholds remained in place for several specialized categories.
Table 2. Minimum income by HQS category
| HQS category | Minimum income | Period |
|---|---|---|
| General category, including corporate top management | 750,000 rubles | Per quarter |
| Researchers and university lecturers; physicians at accredited institutions | 83,500 rubles | Per month |
| Specialists at accredited IT companies | 83,500 rubles | Per month |
| Residents of technology-innovation Special Economic Zones (SEZs) | 58,500 rubles | Per month |
| Medical, teaching, and research staff of the international medical cluster | 1,000,000 rubles | Per year |
| Participants in Skolkovo projects and the Sirius federal territory | No income requirement | — |
The move to quarterly assessment created a transition issue in the first quarter of 2024. Because the law took effect mid-quarter, the Ministry of Internal Affairs clarified that the full 750,000-ruble threshold had to be met cumulatively across January, February, and March. Employers who had paid an HQS specialist 167,000 rubles a month in January and February were required to bring the March payment up to the level needed to close the full quarterly threshold.
Under Article 129 of the Labor Code, the income used for migration compliance includes not only base salary but also compensation and incentive payments, including quarterly and annual bonuses. This gives finance directors flexibility in structuring pay, but the company must report the actual amounts to the MVD on time; an underpayment risks a two-year ban on hiring HQS staff.
If a company cannot maintain the required income level, HQS status is lost and the executive must be transferred to a standard work permit. That requires a labor quota, unless the position is on the quota-exempt list, and the process takes months rather than weeks. In pharma, where a delay in appointing the person responsible for pharmacovigilance or the Qualified Person for quality can stall a drug registration or derail a distribution contract, keeping HQS status is a matter of operational continuity.
Progressive PIT Scale from 2025
From 1 January 2025, Federal Law No. 176-FZ of 12 July 2024 replaced the flat PIT rate with a five-tier progressive scale. For foreign nationals holding HQS status, the new scale applies at the same rates as for tax residents, regardless of how many days they have actually spent in Russia.
Table 3. Progressive PIT scale from 2025
| Annual income | Rate | Cumulative tax calculation |
|---|---|---|
| Up to 2.4 million rubles | 13% | 13% of the base |
| 2.4 to 5 million rubles | 15% | 312,000 rubles + 15% of the amount over 2.4 million |
| 5 to 20 million rubles | 18% | 702,000 rubles + 18% of the amount over 5 million |
| 20 to 50 million rubles | 20% | 3,402,000 rubles + 20% of the amount over 20 million |
| Over 50 million rubles | 22% | 9,402,000 rubles + 22% of the amount over 50 million |
The old advantage of a flat 13% from day one has effectively disappeared for high earners. A director on 24 million rubles a year (2 million a month) will land on an effective rate of roughly 17-18% by year end, against the flat 13% withheld before 2025. Companies that offer tax equalization to their foreign executives have seen the cost of keeping an expat in Russia rise.
Indefinite Residence Permits and Filing Deadlines
From 6 January 2024, FL-316 gave HQS holders and their families the right to obtain an indefinite residence permit. Three conditions apply: the specialist must have worked in Russia as an HQS for at least two years; they must have held a temporary residence permit issued on the basis of their HQS work permit for that entire period; and the employer’s record of tax and social-contribution payments for the specialist must be free of violations throughout.
An indefinite residence permit removes the dependency on work-permit renewals. The specialist can change employer, the company no longer has to track the quarterly salary threshold for migration purposes, and a work permit is no longer required at all. For pharmaceutical holding companies, this is a genuine retention tool for directors who already understand the EAEU market and are running local projects.
The same law also tightened a separate deadline. An HQS specialist must collect the physical work permit card in person within 30 calendar days of the MVD’s decision to issue it. The clock runs from the approval date, not from the date of entry into Russia. Missing the deadline revokes the permit, even if the specialist is already in the country and has signed an employment contract.
For family members of an HQS (spouse, children, parents, and several other categories listed in Article 13.2 of FL-115), the process is simpler. The initial medical exam on entry stays mandatory. Annual repeat exams for family members are waived as long as they remain in Russia continuously. Fingerprinting is done once. The HQS and their family are also exempt from local address registration for the first 90 days after entry, and if they relocate within the country, for example from a plant outside Moscow to a facility in Yaroslavl, the company has up to 30 days to register the new address.
Restrictions and Risks Specific to the Pharmaceutical Sector
Retail pharmacy trade is effectively closed to foreign nationals. The government’s annual decree on the permitted share of foreign workers by economic activity sets a 0% share for retail sale of pharmaceuticals (OKVED code 47.73, the Russian classifier code for pharmacies). For 2026 this is set by Government Decree No. 1995 of 5 December 2025. HQS status does not exempt a specialist from this rule: a foreign top executive cannot legally head a pharmacy chain or hold a position tied directly to dispensing medicines at retail. The restriction does not apply to wholesale distribution.
For manufacturing roles, HQS status remains a practical hiring tool. Russia’s «Pharma-2030» strategy calls for significant medicines to be produced domestically through a full manufacturing cycle by 2030, and foreign engineers and process specialists from headquarters take part in commissioning equipment at Russian sites. Qualified Persons working to GMP standards often oversee the local quality team. Here, qualifications and hands-on experience matter more than nationality.
From 2026, a points-based system evaluates the level of localization of pharmaceutical manufacturing (Government Decree No. 1392 of 10 September 2025). A company confirms its status as a Russian manufacturer with a document from the Ministry of Industry and Trade (Minpromtorg) listing the production stages it actually performs. A foreign production director or technical director holding HQS status is responsible, in this system, for making sure the operations declared in that document are genuinely carried out at the site in the EAEU.
Currency rules also need attention when paying a foreign executive. An HQS salary must be paid strictly in rubles into a Russian bank account; paying any part of it in foreign currency is an illegal currency transaction. Rules for personal transfers abroad differ by the specialist’s citizenship. The Bank of Russia lifted transfer limits for Russian citizens and residents of friendly states on 8 December 2025. For non-residents from non-friendly states (the EU, the US, the UK, and others), a narrower corridor remains: a working specialist may transfer abroad an amount up to their salary, and this limit is extended through 7 December 2026. Separately, a cap on withdrawing cash foreign currency from accounts opened before 9 March 2022 stays in force until 9 September 2026.
Regulatory risk and HR risk are closely linked here. If the HQS status of a technical director or a Qualified Person is revoked over a missed MVD filing, that person loses the legal right to be in Russia and to perform their duties. At the next GMP inspection, Minpromtorg or a foreign auditor then has a direct reason to question the stability of the site’s quality system. Restoring HQS status takes weeks; an inspection or a registration deadline will not wait.
Errors in reporting to the MVD or the banks cost a company dearly. Under Part 5 of Article 18.15 of the Administrative Offenses Code, failing to file, or filing incorrectly, the quarterly notification of an HQS specialist’s salary carries a fine of 35,000 to 70,000 rubles for the responsible officer and 400,000 to 1,000,000 rubles for the legal entity. Employing a foreign national without the required labor permit, under Part 2 of the same article, carries a fine of 250,000 to 800,000 rubles for the legal entity, or suspension of operations for 14 to 90 days.
Article 193.1 of the Criminal Code separately establishes criminal liability for currency transactions carried out with falsified documents. The General Director, who signs the payment orders to a foreign parent company, carries personal exposure here.
Action Plan
The five steps below address the main risks of the reform: underpaying the new threshold, miscalculating PIT, missing the window for an indefinite residence permit, hiring into a restricted retail role, and a late MVD filing.
Recalculate compensation packages for current HQS staff against the new thresholds. Sort staff by category (general, IT, research, SEZ, medical cluster, Skolkovo/Sirius) and check whether the quarterly total, including bonuses and allowances, meets the required minimum.
Set up cumulative PIT calculation. Make sure the accounting system (1C or an equivalent, Russia’s standard payroll and accounting platform) correctly tracks a director’s salary as it crosses the 2.4 million, 5 million, 20 million, and 50 million ruble thresholds over the year and withholds tax at the correct rate at each stage.
Plan the move to an indefinite residence permit for staff worth retaining. For specialists who have completed two years on a temporary residence permit without violations in tax and contribution payments, start the paperwork early rather than waiting for the next work-permit renewal.
Check any retail-facing role against the 0% quota for pharmacy retail. Before placing an HQS specialist in a role tied to dispensing medicines at retail, check the company’s registered activity codes and the specialist’s actual duties against the current-year decree on the permitted share of foreign workers. Wholesale and manufacturing roles are not affected.
Build a calendar for quarterly MVD filings and currency compliance. Assign someone to file the HQS salary notification no later than the last business day of the month following each quarter, and to check every payment to a non-resident against the Bank of Russia’s current limits. A single late or incorrect filing can cost up to 1 million rubles in fines and a two-year ban on hiring new HQS staff.
The entry threshold for HQS status has risen, and administration has become more demanding. For a pharmaceutical company building manufacturing localization into its «Pharma-2030» plans, the status remains a working tool for hiring foreign talent. An indefinite residence permit and quota-free entry outweigh the higher tax and reporting burden, provided HR and finance operate under the 2024-2026 rules rather than the older ones.
Hiring foreign top management rarely stops at migration status. Screening a candidate before signing, the risks of hiring medical representatives through staffing agencies, and a general director’s personal liability for currency transactions are covered in other articles in the Partners & People cluster. Together with this one, they form a broader map of risk in managing foreign personnel at a pharmaceutical company.
Regulatory Framework:
1. Federal Law No. 115-FZ of 25 July 2002, «On the Legal Status of Foreign Citizens in the Russian Federation,» Article 13.2
2. Federal Law No. 316-FZ of 10 July 2023
3. Federal Law No. 176-FZ of 12 July 2024
4. Tax Code of the Russian Federation, Article 224
5. Labor Code of the Russian Federation, Article 129
6. Administrative Offenses Code of the Russian Federation, Article 18.15
7. Criminal Code of the Russian Federation, Article 193.1
8. Government of the Russian Federation Decree No. 1995 of 5 December 2025
9. Government of the Russian Federation Decree No. 1392 of 10 September 2025
10. Bank of Russia information notices of 5 December 2025 and 6 March 2026